The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

CCRIS 5426     (7R,9S)-7-(4-amino-6-methyl- oxan-2-yl)oxy...

Synonyms: LS-94129, BRN 1415739, AC1L2C2S, Esorubicin [INN], 4'-Deoxyadriamycin, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of CCRIS 5426

 

High impact information on CCRIS 5426

 

Chemical compound and disease context of CCRIS 5426

 

Biological context of CCRIS 5426

 

Anatomical context of CCRIS 5426

 

Associations of CCRIS 5426 with other chemical compounds

 

Gene context of CCRIS 5426

 

Analytical, diagnostic and therapeutic context of CCRIS 5426

  • Phase II trials with esorubicin in this dosage schedule are clearly warranted in a wide variety of metastatic neoplasms including a substantial population of patients who have not received prior chemotherapy [25].
  • A method for the simultaneous measurement of the new anthracycline derivative 4'-deoxydoxorubicin and its metabolites by reversed phase liquid chromatography [26].
  • One hundred thirty-six patients with histologically or cytologically documented non-small cell lung cancer or advanced breast cancer were enrolled in two concurrent CALGB clinical trials using esorubicin at a dose of 30 mg/m2 administered intravenously every 21 days [27].

References

  1. Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study. Miller, T.P., Dahlberg, S., Salmon, S.E., Williamson, S.K., Belt, R.J., Dana, B.W., Fisher, R.I. J. Clin. Oncol. (1991) [Pubmed]
  2. Amiodarone-induced enhancement of doxorubicin and 4'-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Chauffert, B., Martin, M., Hammann, A., Michel, M.F., Martin, F. Cancer Res. (1986) [Pubmed]
  3. Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia. Kreis, W., Rottach, C., Budman, D.R., Chan, K., Schulman, P., Allen, S.L., Weiselberg, L., Vinciguerra, V. Cancer Res. (1988) [Pubmed]
  4. New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse. Giuliani, F.C., Kaplan, N.O. Cancer Res. (1980) [Pubmed]
  5. Antitumor activity of esorubicin in human tumor clonogenic assay with comparisons to doxorubicin. Salmon, S.E., Young, L., Soehnlen, B., Liu, R. J. Clin. Oncol. (1984) [Pubmed]
  6. Growth state-specific responsiveness of primary cultures of a nude mouse-xenografted human colon carcinoma to 4'-deoxydoxorubicin and a crude human leukocyte alpha-interferon preparation. van der Bosch, J., Zirvi, K.A. Cancer Res. (1982) [Pubmed]
  7. In vitro responses of nude mouse-xenografted human colon carcinomas exposed to doxorubicin derivatives in tissue culture and in the mouse. Zirvi, K.A., van der Bosch, J., Kaplan, N.O. Cancer Res. (1982) [Pubmed]
  8. Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy. A Southwest Oncology Group study. Green, J.B., Green, S., O'Toole, R.V., Alberts, D.S., Nahhas, W.A., Wallace, D.L. Investigational new drugs. (1991) [Pubmed]
  9. Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach. Somlo, G., Doroshow, J., Akman, S., Leong, L., Margolin, K., McNamara, M., Multhauf, P., Blayney, D., Morgan, R., Raschko, J. Investigational new drugs. (1991) [Pubmed]
  10. Reduction of adriamycin cardiotoxicity by a new cardiotonic agent. Andreani, A., Bossa, R., Galatulas, I., Ninci, M.A., Rambaldi, M. Anticancer Res. (1991) [Pubmed]
  11. New anthracycline analogs in advanced breast cancer. Bonfante, V., Ferrari, L., Brambilla, C., Rossi, A., Villani, F., Crippa, F., Valagussa, P., Bonadonna, G. European journal of cancer & clinical oncology. (1986) [Pubmed]
  12. Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin). Dodion, P., Davis, T.A., Rozencweig, M., Crespeigne, N., Kenis, Y., Bachur, N.R. Investigational new drugs. (1985) [Pubmed]
  13. The effect of adriamycin and 4'-deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids. Kerr, D.J., Wheldon, T.E., Kerr, A.M., Freshney, R.I., Kaye, S.B. Br. J. Cancer (1986) [Pubmed]
  14. Different responsiveness of normal and leukemic hemopoietic cells to esorubicin. Bagnara, G.P., Rocchi, P., Zauli, G., Vitale, L., Licia, G., Damiano, R., Paolucci, G. Anticancer Res. (1988) [Pubmed]
  15. Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro. Dorr, R.T., Shipp, N.G., Lee, K.M. Anticancer Drugs (1991) [Pubmed]
  16. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. McGuire, W.P., Blessing, J.A., Yordan, E., Beecham, J. Investigational new drugs. (1989) [Pubmed]
  17. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study. Vaughn, C.B., Salmon, S.E., Fleming, T.R. Investigational new drugs. (1990) [Pubmed]
  18. Cytotoxic effect of dose and schedule on normal murine hematopoietic progenitor cells following the administration of 4'-deoxydoxorubicin. Pannacciulli, I., Muzzulini, C., Massa, G., Bogliolo, G. Br. J. Cancer (1984) [Pubmed]
  19. 4'-Deoxydoxorubicin (esorubicin) in non-Hodgkin's lymphomas and plasma cell tumors: first evidence of activity. Zagonel, V., Tirelli, U., Sorio, R., Frustaci, S., Pacciarini, M.A., Di Pietro, N. Haematologica (1987) [Pubmed]
  20. Method for the determination of 4'-deoxydoxorubicin, 4'-deoxydoxorubicinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography. Cummings, J. J. Chromatogr. (1985) [Pubmed]
  21. Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance. Genne, P., Coudert, B., Pelletier, H., Girardot, C., Martin, F., Chauffert, B. Anticancer Res. (1989) [Pubmed]
  22. A randomized phase II study of acivicin and 4'deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study. Falkson, G., Cnaan, A., Simson, I.W., Dayal, Y., Falkson, H., Smith, T.J., Haller, D.G. Am. J. Clin. Oncol. (1990) [Pubmed]
  23. Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature. Diehl, L.F., Banks, A., Carter, W., Klein, M.A., Muss, H.B., Weiss, R.B. Cancer Chemother. Pharmacol. (1988) [Pubmed]
  24. Absence of generation of oxygen-containing free radicals with 4'-deoxydoxorubicin, a non-cardiotoxic anthracycline drug. Dickinson, A.C., DeJordy, J.O., Boutin, M.G., Teres, D. Biochem. Biophys. Res. Commun. (1984) [Pubmed]
  25. Phase I trial of esorubicin (4'deoxydoxorubicin). Garewal, H.S., Robertone, A., Salmon, S.E., Jones, S.E., Alberts, D.S., Brooks, R. J. Clin. Oncol. (1984) [Pubmed]
  26. A method for the simultaneous measurement of the new anthracycline derivative 4'-deoxydoxorubicin and its metabolites by reversed phase liquid chromatography. Peng, Y.M., Alberts, D.S., Salmon, S.E., Davis, T.P. Investigational new drugs. (1984) [Pubmed]
  27. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report. Ringenberg, Q.S., Propert, K.J., Muss, H.B., Weiss, R.B., Schilsky, R.L., Modeas, C., Perry, M.C., Norton, L., Green, M. Investigational new drugs. (1990) [Pubmed]
 
WikiGenes - Universities